Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EC Says ‘Bolar Exemption’ Should Cover Pricing, Reimbursement & HTA Processes

Executive Summary

Pricing and reimbursement processes as well as health technology assessments should be explicitly included in the procedures that can be conducted for generic and biosimilar products without infringing patent rights, according to the European Commission’s legislative revision proposals.

You may also be interested in...



Medicines For Europe Calls For A Medicines Security Act

The EU would benefit from the creation of a Medicines Security Act to enable equitable access to affordable medicines and active pharmaceutical ingredients across the bloc, Medicines for Europe has said.

EU Pharma Revision Proposals Still Awaiting Start Of Legislative Debate

The texts of the proposals cannot be formally presented to the European Parliament until they have been translated into all of the EU’s official languages.

EU Reforms Offer Mixed Blessings For Generics And Biosimilars

A long-awaited package of European pharmaceutical legislation reforms unveiled by the European Commission contains a number of measures that will affect the generics and biosimilars industry – including changes to regulatory data protection periods, simplified marketing authorization procedures, and moves towards greater digitalization.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152828

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel